EUVIMEDEUVIMED entdecken
Systematische Übersicht

Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review

Chengcheng Fu, Jia Chen, Yang Xu, Depei Wu

Clinical and Investigative Medicine · 27.03.2018 · 41 (1) · E5-E15

DOI: 10.25011/cim.v41i1.29458 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical and Investigative Medicine, erschienen am 27.03.2018. Verfasst von Chengcheng Fu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188# Shizi Street, Suzhou, China.. em…. Hauptthemen laut MEDLINE: Heart Transplantation, Hematopoietic Stem Cell Transplantation, Lung Transplantation. Die Arbeit wurde bisher 5-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this retrospective study was to analyze the dose adjustment of immunosuppressants (cyclosporine, tacrolimus and sirolimus) for the patients with allogeneic hematopoietic stem cell and solid-organ (heart/lung) transplantation during co-administration of posaconazole.

Methods

MEDLINE, EMBASE and Cochrane Library were searched from January 1, 2000 to June 30, 2017 for clinical reports of patients who received allogeneic hematopoietic stem cell and organ transplantation and were co-administered posaconazole and immunosuppressants (cyclosporine, tacrolimus or sirolimus).

Results

Seven studies were included in the systematic review with a total of 215 patients. Five studies involved hematopoietic stem cell transplant, one heart transplant and one lung transplant. In general, the co-administration of posaconazole with sirolimus, tacrolimus or cyclosporine necessitated immunosuppressant dose reductions to maintain the levels of the drug in the optimal therapeutic range. Reported dose reductions were 50%–68% for sirolimus, 75% for tacrolimus and 14%–49% for cyclosporine. The findings were similar for hematopoietic stem cell, heart or lung transplantation studies.

Conclusion

Our findings indicate that, when posaconazole is co-administered, the dosage of sirolimus and tacrolimus should be reduced by 60%–70% and for cyclosporine and by 30%–40% following allogeneic hematopoietic stem cell and solid-organ transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart TransplantationHematopoietic Stem Cell TransplantationLung TransplantationDrug Therapy, CombinationHumansImmunosuppressive AgentsTriazoles

Substanzen

Immunosuppressive AgentsTriazolesposaconazole

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188# Shizi Street, Suzhou, China.. email@email.com.

Zitieren

APA

Fu, C., Chen, J., Xu, Y., & Wu, D. (2018). Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review. Clinical and Investigative Medicine, 41(1), E5-E15. https://doi.org/10.25011/cim.v41i1.29458

Vancouver

Fu C, Chen J, Xu Y, Wu D. Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review. Clinical and Investigative Medicine. 2018;41(1):E5-E15. doi:10.25011/cim.v41i1.29458

BibTeX
@article{Fu2018,
  author = {Fu, Chengcheng and Chen, Jia and Xu, Yang and Wu, Depei},
  title = {Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review},
  journal = {Clinical and Investigative Medicine},
  year = {2018},
  volume = {41},
  number = {1},
  pages = {E5--E15},
  doi = {10.25011/cim.v41i1.29458}
}
Kostenlos starten →